Oklo, Atomic Alchemy Target 2026 Criticality for Pilot Isotope Reactors

Atomic Alchemy is pushing toward a July 4, 2026 criticality date for its Groves Isotopes Test Reactor in Lockhart, Texas, while parent company Oklo Inc. has engineered a faster near-term revenue play from a separate facility in Idaho that could generate its first commercial cash flow before a single chain reaction occurs at the Texas site.

The Groves VIPR, short for Versatile Isotope Production Reactor, is a 15-MWt pool-type, water-cooled, nonpressurized reactor burning low-enriched uranium. Atomic Alchemy, which Oklo acquired in 2025 and which was selected for the Department of Energy's Reactor Pilot Program that same year, describes Groves as a test platform designed to generate the operating experience required before scaling to production-level VIPRs. That distinction matters for anyone reading the milestone calendar: the July 4 date is not a commercial launch, it is the data collection starting gun for the next round of investment and deployment decisions.

On the regulatory side, DOE has approved a Nuclear Safety Design Agreement under its Reactor Pilot Program for the Groves project, a milestone that signals DOE concurrence that the design is ready for the next phase of safety documentation and preliminary safety analyses. Oklo also received a second NSDA covering its Aurora powerhouse at Idaho National Laboratory, announced in the same press release cycle. Both approvals matter, but neither is an NRC operating license. The DOE's Reactor Pilot Program pathway runs parallel to NRC licensing, not through it, which means the Groves authorization framework is newer and less battle-tested than the standard NRC construction permit route.

The most exposed gate between now and July 4 is straightforward but unresolved: procurement. The Caldwell County site structure is complete, and the reactor tank is installed at the Lockhart location inside the planned Proto-Town Innovation Hub development. But electrical systems, plumbing, and auxiliary equipment procurement remain outstanding. No specific completion schedule for that work has been stated publicly, which leaves a compressed runway heading into summer.

The Idaho Radiochemistry Laboratory is the revenue narrative that does not depend on Groves going critical on schedule. On March 17, Oklo announced that the NRC had issued Atomic Alchemy a materials license allowing the Idaho facility to handle, process, manufacture, and distribute a limited amount of select isotopes. CEO Jacob DeWitte said the Idaho facility "is expected to make first revenue this year." That makes the Idaho lab the first cash-flow asset in Oklo's isotope portfolio, generating commercial activity through exclusive NRC licensing while Groves navigates the DOE authorization track in Texas.

The peer comparison reveals where Oklo genuinely leads and where claims outpace paperwork. Kairos Power holds an NRC construction permit for its Hermes fluoride salt-cooled test reactor, issued in December 2023, and targeted 2026 operations with TRISO fuel sourced from DOE material. TerraPower secured an NRC construction permit for its 345-MWe Natrium sodium-cooled reactor in Wyoming in partnership with GE Vernova Hitachi Nuclear Energy. Both companies are working through the traditional NRC licensing track at larger scale. Oklo's DOE pathway for Groves is faster on paper, but it is moving through a framework that has not yet taken any reactor from NSDA approval to criticality. On the isotope-production-specific lane, however, no peer company has an active NRC materials license for isotope manufacturing at the radiochemistry level that Oklo now holds in Idaho.

Criticality in July would represent a real first for the Reactor Pilot Program and deliver the operational data that underpins any serious argument for production-scale VIPR deployment. But reliable isotope output, continued NRC and DOE safety compliance, and a scaled LEU supply chain are all required milestones before Groves shifts the needle on U.S. domestic supply for medical imaging, cancer therapy, and industrial isotope users. The Idaho lab's materials license means Oklo does not have to wait for July 4 to start writing that supply chain story.